Atea Pharmaceuticals
AVIR
130 hedge funds and large institutions have $190M invested in Atea Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 43 increasing their positions, 48 reducing their positions, and 17 closing their positions.
290% more call options, than puts
Call options by funds: $187K | Put options by funds: $48K
1% less funds holding
Funds holding: 131 → 130 (-1)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
1.29% less ownership
Funds ownership: 69.43% → 68.14% (-1.3%)
10% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 48
32% less capital invested
Capital invested by funds: $278M → $190M (-$88M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$4.07M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.96M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.78M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$984K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$620K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.09M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$4.63M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.23M |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$1.26M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
-$842K |
AVIR Hedge Fund Activity: Q1 2023 in Review
130 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q1 2023, worth a combined $190M — down 32% from $278M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of AVIR and 16 opened new positions — a net loss of 1 holder — while 48 trimmed existing stakes and 43 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $4.07M. The largest seller was Vanguard Group, cutting an estimated $6.09M.
- 130 institutional investors held Atea Pharmaceuticals (AVIR) as of Q1 2023, down from 131 in Q4 2022.
- Funds reported $190M of Atea Pharmaceuticals stock for Q1 2023, down 32% quarter-over-quarter.
- 16 funds opened new Atea Pharmaceuticals positions in Q1 2023 and 17 closed out, a net change of -1 holder.
- The largest Atea Pharmaceuticals buyer in Q1 2023 was Tang Capital Management, an estimated $4.07M added.
- The largest Atea Pharmaceuticals seller in Q1 2023 was Vanguard Group, an estimated $6.09M sold.
Based on aggregated 13F filings for Q1 2023.